Heidelberg Pharma AG

Heidelberg Pharma AG: Heidelberg Pharma AG (HPHA, Frankfurt Stock Exchange), based in Ladenburg, Germany, is a leading biotech company pioneering the use of its ATAC (Antibody Targeted Amanitin Conjugate) platform to develop novel cancer treatments with a unique mode of action effective at specifically killing both inactive and dividing cancers cells and overcoming tumor resistance mechanisms. The platform can be applicable across many cancer types and has a specific genetic biomarker that confers high tumor cell susceptibility to the therapy in many cancer types. Heidelberg Pharma is accelerating development of an internal pipeline of ATACs. Lead product HDP-101, for blood cancer, is expected to start clinical development early 2021. It is also out-licensing the ATAC technology to other companies using the partners’ antibodies to create new ATACs. These partnerships are expected to generate long term income streams and early technology validation.
Based in...
Clinical Stage
Pre-Clinical Stage
Disease Space
Immuno-Oncology, Men's Health
Europe, Public
Market Cap
100MM - 500MM
Therapeutic Modalities
Gregor-Mendel-Str. 22
Ladenburg, 68526

Company Participants at European Biotech Investor Day 2020

  • Jan Schmidt-Brand, JD, CEO

Top 10 Holders of Heidelberg Pharma AG

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Gutmann Finanz Strategien AG 0.06 17,800 0.00 Funds 12/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.